Osanetant Sanofi-Synthélabo.

Abstract

Osanetant is a neurokinin (NK3) receptor antagonist under development by Sanofi-Synthélabo (formerly Sanofi) as a potential treatment for schizophrenia [328910]. Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety [169511]. Following phase IIa clinical trials [307656], [328910], [359231], osanetant entered phase IIb development in February 2001 [409432]. Osanetant was the first potent and selective non-peptide antagonist described for the NK3 tachykinin receptor [176305]. It has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors [176305]. In October 1999, Lehman Brothers predicted that the probability of the product reaching the market was 10%, with a possible launch in 2003 and potential peak sales of US $200 million in 2011 [346267].

• Authors: F Kamali
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 7 Pg. 950-6 (Jul 2001) ISSN: 1472-4472 [Print] England
• PMID: 11757797 (Publication Type: Journal Article, Review)

Chemical References

• Antipsychotic Agents
• Piperidines
• Receptors, Neurokinin-3
• Tachykinins
• SR 142801
• Acetylcholine
• Dopamine

Topics

• Acetylcholine (metabolism)
• Animals
• Antipsychotic Agents (chemical synthesis, metabolism, pharmacology)
• Brain (metabolism)
• Cardiovascular System (metabolism)
• Dopamine (metabolism)
• Humans
• Piperidines (chemical synthesis, metabolism, pharmacology)
• Receptors, Neurokinin-3 (antagonists & inhibitors, metabolism, physiology)
• Schizophrenia (drug therapy)
• Stereoisomerism
• Structure-Activity Relationship
• Tachykinins (metabolism, physiology)